Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice

International Journal of Clinical Rheumatology

Volumn 5, Issue 5, 2010, Pages 581-591

  Schiff, Michael ^c   Poncet, Coralie ^a   Bars, Manuela Le ^b  

^a Docs International   (France)

^b BRISTOL MYERS SQUIBB   (United States)

^c NONE

Author keywords

abatacept; biologic disease modifying antirheumatic drugs; Clinical Disease Activity Index; clinical practice; Disease Activity Score 28; patient retention; rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CLINICAL PRACTICE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; INFECTION; LUNG CANCER; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PNEUMONIA; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; UNITED STATES; UTERUS CANCER;

EID: 77958039084     PISSN: 17584272     EISSN: None     Source Type: Journal    
DOI: 10.2217/ijr.10.52     Document Type: Article

References (19)

1. Calguneri M, Pay S, Caliskaner Z et al.: Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 17(6), 699-704 (1999).
2. Buch MH, Bingham SJ, Bryer D, Emery P: Long-term infliximab treatment in rheumatoid arthritis: Subsequent outcome of initial responders. Rheumatology (Oxford) 46(7), 1153-1156 (2007).
3. Yamada A, Salama AD, Sayegh MH: The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. 13(2), 559-575 (2002).
4. Westhovens R, Robles M, Ximenes AC et al.: Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis. 68(12), 1870-1877 (2009).
5. Kremer JM, Genant HK, Moreland LW et al.: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann. Intern. Med. 144(12), 865-876 (2006).
6. Kremer JM, Genant HK, Moreland LW et al.: Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 58(4), 953-963 (2008).
7. Genovese MC, Becker JC, Schiff M et al.: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor-a inhibition. N. Engl. J. Med. 353(11), 1114-1123 (2005).
8. Genovese MC, Schiff M, Luggen M et al.: Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann. Rheum. Dis. 67(4), 547-554 (2008).
9. Schiff M, Pritchard C, Huffstutter JE et al.: The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: The ARRIVE trial. Ann. Rheum. Dis. 68(11), 1708-1714 (2009).
10. Zink A, Listing J, Kary S et al.: Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann. Rheum. Dis. 64(9), 1274-1279 (2005).
11. Zink A, Strangfeld A, Schneider M et al.: Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum. 54(11), 3399-3407 (2006).
12. Kievit W, Fransen J, Oerlemans AJ et al.: The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann. Rheum. Dis. 66(11), 1473-1478 (2007).
13. Fransen J, van Riel PL: The Disease Activity Score and the EULAR response criteria. Clin. Exp. Rheumatol. 23(5 Suppl. 39), S93-S99 (2005).
14. Aletaha D, Smolen JS: The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract. Res. Clin. Rheumatol. 21, 663-675 (2007).
15. Gibofsky A, Kremer JM, Moniz Reed D, Reed G, Klem C, Greenberg J: Early experience with abatacept in a US observational cohort: Clinical and patient report outcomes from the CORRONA registry. Arthritis Rheum. 58(9), S309 (2008) (Abstract 380).
16. Gyger G, Raunaud JP: Abatacept use in daily practice: Report on the first six months of utilization in 50 patients from the RHUMADATA database. Arth. Rheum. Program book supplement Abstract 560, F106 (2008).
17. van der Heijde DM, van't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB: Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann. Rheum. Dis. 51(2), 177-181 (1992).
18. Schiff MH, Pritchard C, Huffstutter JE et al.: The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-TNF therapy or were directly switched to abatacept: The ARRIVE trial. Ann. Rheum. Dis. 68(11), 1708-1714 (2008).
19. Sibilia J, Westhovens R: Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 25(5 Suppl. 46), S46-S56 (2007).